News

January 26, 2021

Novartis goes up against Glaxo in Tim-3

January 25, 2021

Merck’s Covid-19 vaccines head for the scrapheap

Merck & Co’s move illustrates how hard it will be for the second wave of Covid-19 vaccine candidates to succeed.

January 25, 2021

Aurinia adds icing to the cake with clean lupus approval

January 25, 2021

Roche keeps its eyes on the prize with second faricimab win

January 22, 2021

Boston adds to furious deal-making pace

January 22, 2021

Biotech deal premiums still punchy

January 21, 2021

Lilly Blazes a trail in Covid-19 prevention

January 21, 2021

Biopharma’s stock market winners and losers in 2020

January 21, 2021

Merck KGaA’s dual immuno-oncology weapon misfires

Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.

January 21, 2021

Haemonetics and Hillrom deals add to medtech’s 2021 M&A fever

January 20, 2021

Glaxo joins the Covid-19 delay queue

Load More